UPDATE: Eiger BioPharmaceuticals (EIGR) Tops Q1 EPS by 19c
Eiger BioPharmaceuticals (NASDAQ: EIGR) reported Q1 EPS of ($0.84), $0.19 better than the analyst estimate of ($1.03).
"The Eiger HDV program is moving into Phase 3 with a single, international, multi-center registration trial of approximately 300 HDV infected patients called D-LIVR (Delta Liver Improvement and Virologic Response in HDV)," said David Cory, President and CEO. "We plan to complete agency discussions and communicate final details of the D-LIVR study by mid-year."
First Quarter 2018 Financial Results
- Net loss for the first quarter of 2018 was $8.8 million, or $0.84 per share basic and diluted, compared to a net loss of $11.2 million, or $1.34 per share basic and diluted for the first quarter of 2017.
- Research and development expenses for the first quarter of 2018 were $5.5 million compared to $7.5 million for the first quarter of 2017, a decrease of $2.0 million. The decrease was primarily due to a $2.0 million reduction in clinical and drug supply expenditures.
- General and administrative expenses for the first quarter of 2018 were $3.0 million compared to $3.5 million for the first quarter of 2017, a decrease of $0.5 million. The decrease was primarily due to a $0.4 million decrease in stock-based compensation expense.
- As of March 31, 2018, Eiger had cash, cash equivalents and short-term debt securities of $33.2 million, compared to $41.8 million at December 31, 2017.
For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.